| Description | Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye. |
| Synonyms | SHP-606 sodium, SAR1118-023 sodium, SAR 1118-023 sodium, SAR-1118-023 sodium, Xiidra sodium |
| molecular weight | 637.46 |
| Molecular formula | C29H23Cl2N2NaO7S |
| CAS | 1119276-80-0 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 80 mg/mL (125.50 mM), Sonication is recommended. DMSO: 80 mg/mL (125.50 mM), Sonication is recommended. |
| References | 1. Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15. 2. Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. 3. Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin(STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5198-204. 4. Hussar DA, Cheeseman RS 2nd. Lifitegrast, Bezlotoxumab, and Sugammadex sodium. J Am Pharm Assoc (2003). 2017 Mar-Apr;57(2):284-287. |